NCT05558696CompletedPhase 2
A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)
A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bomedemstat in Patients With Polycythemia Vera (PV)
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
This study will evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of the orally administered lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat, in participants with polycythemia vera (PV). At Week 36 of dosing, participants will be assessed for eligibility to receive additional treatment through Week 52. Participants deriving clinical benefit and safely tolerating bomedemstat will qualify for continued treatment at the Investigator's discretion.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 20 Sept 2022
- Start date
- 7 Sept 2023
- Primary completion date
- 24 Mar 2025
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT05558696
- EudraCT number
- 2022-002262-32
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 20
- From 7 Sept 2023 to the primary completion date, 24 Mar 2025
- 17 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Has unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1)
Other illness
- Has an uncontrolled active infection
- Has a known human immunodeficiency virus (HIV) infection or active Hepatitis A, Hepatitis B or Hepatitis C virus infection
- Has evidence of increased risk of bleeding, including known bleeding disorders
Other
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or greater
- Is pregnant or lactating
Who the study is looking for
- Has a diagnosis of Polycythemia Vera per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms
- Has a bone marrow fibrosis score of Grade 0 or Grade 1
- Has failed at least one standard cytoreductive therapy to lower hematocrit
- Has a life expectancy \>36 weeks
- Has discontinued prior cytoreductive therapy for 2 weeks (4 weeks for interferon) prior to study drug initiation
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (17)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Monash Medical Centre ( Site 0006) Coordinator of this site? Confirm its status | Clayton | Australia | Unknown status |
| Royal Perth Hospital ( Site 0504) Coordinator of this site? Confirm its status | Perth | Australia | Unknown status |
| Sunshine Coast Hematology and Oncology Clinic (Site 0506) Coordinator of this site? Confirm its status | Sunshine Coast | Australia | Unknown status |
| Boston Pilgrim Hospital ( Site 0207) Coordinator of this site? Confirm its status | Boston | United Kingdom | Unknown status |
| Gloucestershire Royal Hospital ( Site 0205) Coordinator of this site? Confirm its status | Gloucester | United Kingdom | Unknown status |
| United Lincolnshire Hospitals NHS Trust ( Site 0204) Coordinator of this site? Confirm its status | Lincoln | United Kingdom | Unknown status |
| Imperial College London ( Site 0025) Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Guys and St Thomas NHS Foundation Trust - Guys Hospital ( Site 0020) Coordinator of this site? Confirm its status | London | United Kingdom | Unknown status |
| Royal Gwent Hospital ( Site 0201) Coordinator of this site? Confirm its status | Newport | United Kingdom | Unknown status |
| University of Michigan Comprehensive Cancer Center ( Site 0008) Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
| Ohio State University Comprehensive Cancer Center ( Site 0103) Coordinator of this site? Confirm its status | Columbus | United States | Unknown status |
| Duke University Medical Center ( Site 0016) Coordinator of this site? Confirm its status | Durham | United States | Unknown status |
| Comprehensive Cancer Centers of Nevada - Peak ( Site 0118) Coordinator of this site? Confirm its status | Las Vegas | United States | Unknown status |
| BRCR Global ( Site 0120) Coordinator of this site? Confirm its status | Plantation | United States | Unknown status |
| OHSU Knight Cardiovascular Institute Cardiology Clinic - South Waterfront ( Site 0102) Coordinator of this site? Confirm its status | Portland | United States | Unknown status |
| Huntsman Cancer Hospital at the University of Utah ( Site 0119) Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
| Hematology Oncology of the North Shore ( Site 0104) Coordinator of this site? Confirm its status | Skokie | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.